ATTENTION!! To all medical related personalities!! Here is a breaking news!!
Medicine is a source of treatment and cure, but small negligence can turn this life saviour into deadly poison 🚫
DRAP(Drug Regulatory Authority of Pakistan) Recalls VALSARTAN from Market
On 12th of July competent authority of Pakistan deals with medicinal and therapeutic goods DRAP-2012 issued a notice to companies to immediately withdraw blood pressure treating medicine containing Valsartan as an Active Pharmaceutical Ingredient from Market because of the presence of carcinogenic impurity in it!!
What is Valsartan?
Valsartan is a generic name of blood vessel constrictor used to treat blood pressure problem, it works by blocking Receptor called Angiotensin and on the contrary it activates another receptor called Aldosterone or vassopressin and ultimately helps to control life threatening fluctuations in blood pressure.
Which impunity found in it?
NDMA (N-Nitrosodimethylamine) found in it after testing.
Is this Harmful ?
Yes! It is, NDMA is a chemical which is carcinogenic in nature I.e. it cause abnormal growth of normal body cells a.k.a Cancer!!
Testing report was issued by EMA (European Medicine Agency)
Valsartan API Manufactured at ZHEIJIANG HUAHAI PHARMACEUTICAL, CHINA
This API is imported by these pharmaceuticals in Pakistan
1. Amarant pharmaceutical
2. Efroze pharmaceutical
3. Safe pharmaceutical
4. High-Q pharmaceutical
5. Genetics pharmaceutical
6. PharmEvo pharmaceutical
7. Tabros pharmaceutical
8. Searl pharmaceutical
9. Sami pharmaceutical
What is the Response of Nominated Pharmaceuticals?
Till now, only Getz Pharmaceutical and Novartis Pharmaceutical issued a public announcements via their media platforms, that their Valsartan containing products are safe to use because API Valsartan is not imported from China.
But no such response from those nominated pharmaceuticals observed yet..
Following copy of announcements attached for your concern